Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 14/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487133 | 0.96 | MEN1 (0.35) | PDK2ACACAMEN1KMT2AKDM4E | |
| SCHEMBL13488159 | 0.92 | PDK2 (0.39) | PDK2ACACAMEN1KMT2AKDM4E | |
| SCHEMBL13487331 | 0.92 | CTRC (0.37) | ACACAMEN1KMT2AKDM4EDHODH | |
| SCHEMBL13487925 | 0.91 | PDK2 (0.41) | PDK2ACACAMEN1KMT2AKDM4E | |
| SCHEMBL13487204 | 0.90 | ENPP1 (0.36) | ACACAMEN1KMT2AKDM4EDHODH | |
| SCHEMBL10300998 | 0.90 | PDK2 (0.39) | PDK2ACACAMEN1KMT2AHPGD | |
| SCHEMBL13487392 | 0.89 | MEN1 (0.36) | PDK2ACACAMEN1KMT2AKDM4E | |
| SCHEMBL13487781 | 0.89 | PDK2 (0.37) | PDK2ACACAMEN1KMT2AKDM4E | |
| SCHEMBL10300988 | 0.89 | PDK2 (0.40) | PDK2ACACAMEN1KMT2A | |
| SCHEMBL13487077 | 0.88 | KDM4E (0.39) | PDK2MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| EP-2108689-A2 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | PDK2 1456/4885ACACA 1675/4885MEN1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.